Healthy Growth Performance

Company Update

PT Kimia Farma Tbk

Q2 – 2020

Speaker

Mr. Pardiman

Finance Director PT Kimia Farma Tbk (KAEF) Indonesian Citizen Education & Training:

Master of Management from Diponegoro University Bachelor of Economics Management from Diponegoro University BUMN Executive Leadership Program IFA Strategic Forum

Employment History:

Finance Director PT Bio Farma (Persero) (2018-2019) Finance Director PT Perum Bulog (2017-2018) Finance Director PT Petrokimia Gresik (2016-2017) President Commisioner PT Kawasan Industri Gresik (2016-2017) Director of Consumer, Micro and Funding PT Bank BRI Syariah (2015-2017)

2

1

2

3

4

MARKET OVERVIEW

COMPANY OVERVIEW

FINANCIAL HIGHLIGHT

BUSINESS EXPANSION & INVESTMENT

Agenda

5 OUR RETAIL BUSINESS-KIMIA FARMA APOTEK

MARKET OVERVIEW

1

Indonesia Pharmaceutical Market (Q2/2020)

Indonesia pharmaceutical market decrease at -1.0% in MAT Q2/2020

Source: IMS IQVIA 2Q/2020

MNC ETHICAL BRANDED,

21.9%

MNC UNBRANDED

GENERIC, 0.1%

DOMESTIC ETHICAL

BRANDED, 30.0%

DOMESTIC UNBRANDED

GENERIC, 17.3%

MNC FREE SALES, 5.2%

DOMESTIC FREE SALES,

25.5%

ETHICAL

69.3%

FREE

SALES

30.7%

In % MAT 2Q19 vs MAT 2Q20 CAGR 4 Y

TOTAL MNC DOMESTIC TOTAL MNC DOMESTIC

TOTAL -1.0 1.7 -1.9 3.9 5.2 3.4

ETHICAL -1.8 0.6 -2.8 4.0 5.4 3.4

ETHICAL BRANDED 1.2 0.9 1.5 3.1 5.6 1.5

UNBRANDED GENERIC -9.8 -33.2 -9.5 6.9 -12.1 7.2

FREE SALES 0.9 6.8 -0.2 3.5 4.1 3.4

16,087 18,017 18,840 18,946

3,836 4,005 4,196 4,481

38,825 41,041

40,782

19,668 21,598

21,983 21,932

8.0

2.8 41,972

-1.0

8

7

6

5

4

3

2

1

0

-1

-2

9

-

20,00

0

10,00

0

50,000

40,000

30,000

60,000

100,000

90,000

80,000

70,000

MAT 2Q17 MAT 2Q19 MAT 2Q20

MNC FREE SALES

DOMESTIC FREE SALES

MAT 2Q18

MNC ETHICAL

DOMESTIC ETHICAL

Growth (%)

• Ethical Branded still growth 1.2% and Free Sales growth 0.9% in MAT Q2/2020, but for the Unbranded Generic decrease -9.8%.

• Unbranded Generic decrease was due to the fact that the budget from Government for Unbranded Generic that should have been spent was diverted to spending on Covid-19 related products, resulting in a fairly high decline.

• This decline can be assumed as a result of the patient paradigm shift from expensive ethical products to BPJS drugs.

-1.0%

-15.2%

MAT Gr QTR Gr

6

Hospital channel has decreased both for MNC and Domestic Company, while in Pharmacy channel, the growth was driven by Domestic Company in MAT Q2 2020.

MAT Q2 2020 VALUE SHARE (PHARMACY, HOSPITAL, DRUGSTORE) – HNA PRICE

43% 43%

65% 65%

33% 32%

26% 27%

5% 5%

32% 35%

24% 22% 30% 30%

26% 24%

7% 8% 0% 0%

9% 9%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

MAT 2Q19 MAT 2Q20

DOMESTIC ETHICAL

MAT 2Q19

DOMESTIC FREE SALES

MAT 2Q20

MNC ETHICAL MNC FREE SALES

Growth

-2.5%

Pharmacy Hospital Drugstore

MAT 2Q19 MAT 2Q20

Channel Value Share in Indonesia (2Q/2020)

Source: IMS IQVIA 2Q/2020

7

0.9% -2.5% -0.5%

COMPANY OVERVIEW

2

Corporate Structure

10

KF : 99.99% KFA: 0.01%

KF : 99.99% YKKKF : 0.01%

KF : 51.00% PTPN VIII: 49.00%

KF : 80.67% SWP : 19.33%

KF : 10.00% Jasindo : 10.00% Bank Mandiri : 80.00% (Equity Capital)

KF : 60.00% MBM : 40.00%

2003 2003 2011 2014 2018 2016

KFA : 99.99% YKKKF: 0.01%

2019

KF : 56.77% Public : 43.23%

Lucas: 99.91% Others: 0.09%

PEHA : 20.00% Others: 80.00%

PEHA: 90.25% Others: 9.75%

* December 31, 2019

Government 9.975%

Public 90.025% 90.025%

PT Bio Farma (Persero)

1 Share Seri A Dwiwarna Government

9.975% Public

* June 30, 2020

Top 20 Pharmaceutical Industry in Indonesia (2Q/2020)

MAT Rank Top 20 Companies Share% Growth%

1 5.9 -5.5

2 5.7 -4.1

3 4.9 -17.0

4 3.0 -4.0

5 2.8 0.1 6 2.4 -18.9

7 2.2 13.8

8 2.1 -3.1

9 2.1 52.5

10 2.0 9.4

11 1.9 -1.8

12 1.9 -7.5

13 1.9 -0.9

14 1.9 5.1

15 1.8 -21.7

16 1.8 13.4

17 1.6 -9.5

18 1.6 -0.3 19 1.6 -20.8

20 1.5 -4.2

+ 1,133 (2.8%)

315 (0.8%)

1,448 (3.6%)

Source: Indonesia Total Market Q2 2020

+ +

628 (1.6%)

1,448 (3.6%)

185 (0.5%)

2,261 (5.7%)

HOLDING BUMN FARMASI

605

628

628

633

710

736

751

753

761

773

797

834

854

892

980

1.133

1.190

1.956

2.305

2.374

PFIZER

DANKOS

BIOFARMA

B.INGELHEIM

DJOJONEGORO C-1000

INTERBAT

ASTRAZENECA

FAHRENHEIT

FERRON PAR PHARM

SANOFI-AVENTIS

BAYER INDONESIA

SOHO

LAPI

DARYA VARIA

NOVARTIS

KIMIA FARMA

NOVELL PHARM

KALBE FARMA

SANBE

DEXA MEDICA

3

4

11

1,133

1,190

1,956

2,305

,374

Integrated Business Chain

Manufacture of

Active Pharmaceutical

Ingredients (API)

Production

Facility

National

Distribution Center

(NDC)

Retail Pharmacy Trading &

Distribution

Clinic & Clinical

Laboratory Customer

Unit Usaha

Business Unit

Sumatera,

Batam Jawa

Bali, Nusa

Tenggara Kalimantan

Sulawesi,

Maluku, Papua Total

Plant 1 10 1 12

Distributor 11 21 3 5 9 49

Retail Pharmacy 217 667 121 130 173 1,308

Clinical Laboratory 11 42 3 6 8 70

Clinic 65 272 24 56 69 486

*June 30, 2020

12

Company Products & Composition Q2/2020

13

OTC & Herbal 8.50%

Cosmetics 15.29%

Generics 47.29%

Ethical 23.18%

API 4.74%

Export 1.00%

Medical Devices 0.00%

OTC & Herbal Ethical

Generic API Medical Device

Cosmetics

OTC & Herbal 10.99%

Cosmetics 7.77%

Generic 49.56%

Ethical 20.94%

API 2.81% Export

0.81%

Medical Devices 7.13%

Q2/2020

Q2/2019

Covid–19 Health and Safety Audits

STAKEHOLDERS

COVID-19 will change business even after the pandemic ends and it is unlikely that everything will return to “NORMAL“ and

now we are entering the “NEW NORMAL” era.

Business will face signifcant calllenges in protecting the “SAFE GUARD Employee and Stakeholders of the Company

from the health and safety risk associated with the spread of COVID-19.

So that the Company must be able to protect and build trust with Employees and Stakeholders, as a form of

transparency and credibility to the Public and Stakeholders.

Currently, the Company is preparing to conduct a Health and Safety Audit related to COVID-19.

18

Certification

Good Manufacturing Practice Plant Watudakon, Medan, Bandung, Jakarta

Good Distribution Practice (GDP) Trading & Distribution

Food Safety System Certification (FSSC) 22000 Plant Kina (SIL)

Halal MUI Certificate Plant Bandung, Semarang, Watudakon, Plant Kina (SIL)

Good Traditional Medicine Manufacturing Practice Plant Bandung, Jakarta

ISO 9001: 2008 Plant Jakarta, Bandung, Watudakon, Medan

Certificate of Suitablity Plant Kina (SIL)

Kosher Certificate Plant Kina (SIL)

Good API Manufacturing Practice Plant Kina (SIL)

ISO 9001: 2015 Plant Semarang, Plant Kina (SIL)

ISO 14001: 2015 Plant Watudakon

Green Environment Certificate Plant Jakarta, Bandung, Watudakon, Medan

20

Award

Top Brand Award

Itech Top Digital Innovation Transformation in Smart Healthcare Business 2019

BUMN Marketers Award The most promising company in tactical

market 2019 The most promising company in strategic

marketing 2019 The most promising company in market

3.0 2019

Musium Rekor Indonesia

(MURI)

CSR

Kimia Farma Apotek Digital Popular Brand Award

The Best Corporate Philantropy for Apung Clinic

Indonesia Best Corporate

Sustainability Initiatives

TOP 50 Company Corporate

Governance Award 2019

IICD Corporate

Governance Award

Indonesia Employers of

Choice Award 2019 The Winner of Indonesian Employers Of

Choice Award 2019 The Winner of Job Seeker by Korn Ferry

2019

Investor Award

HR Excellent Award

2020

Top CSR Award 2020

3 Awards from Top Brand for: Enkasari (Sprue Medicine), Salycil (Health Powder), Asifit products (the category of Breast Milk Booster)

The most of the use of mouthwash with participants simultaneously

Best BUMN 2019 in the category of Non-Financial, Pharmaceutical, Food and Miscellaneous Industries

Winner of the HR Excellence Award, in Category: HR Transformation, with a grade: A from SWA magazine

The best CSR in the pharmaceutical industry. Excellent Program for Local Community Development

Top CSR Award Star # 4 from Top Business, the National Committee on Governance Policy, and the Nawacita Research Institute

21

Long Term Plan Strategy 2020 – 2024

Retail Transformation Supply Chain

Optimization Increase the diversity

of products and portfolios through strategic alliances

Manufacturing Excellence & Digital Initiative

Stabilization and realization of synergies by acquisitions

Addition of BBO Factory Facilities

Commercialization of BBO products

The Banjaran factory is fully operational

Marketing and positioning of existing brands

Additional capacity and products at KFSP

BBO Import reduction Optimization of the

Banjaran Factory Realization of digital

potential throughout the value chain (joint collaboration with digital partners)

Exporter of high value BBO and essential oils

Household name for health and beauty herbal products

Becoming one of the most popular workplaces in Indonesia

The leading choice as an integrated healthcare provider

• Global network and product expansion

2020

2021

2022

2023

2024

22

With a complete business portfolio (end to end) Kimia Farma is committed to creating integrated health services

INTEGRATED HEALTHCARE ECOSYSTEM

1

2

3

4

5 One of the Company's strategies is to conduct a strategic alliance, this strategy is expected to be able to add to the Company's value proposition to complete the healthcare business portfolio

INORGANIC GROWTH

To strengthen the Company's core business, efforts and strategic approaches are carried out in running the business lines

PORTFOLIO OPTIMIZATION

The initiative is in line with the transformation strategy carried out by the Company, the focus for this is: retail transformation, marketing leadership, penetration of modern markets and strategic relationship management

COMMERCIAL EXCELLENCE

Strengthening the entire value chain business in Kimia Farma Group with its main goal is that the process can run more effectively and efficiently

OPERATIONAL EXCELLENCE

Strategic Initiatives 2020

23

FINANCIAL HIGHLIGHTS

3

Peer Performance Q2/2020

5,44

38,05

26,11

3,60

3,10

-1,50

6,70

-1,00 -5,00

0,00

5,00

10,00

15,00

20,00

25,00

30,00

35,00

40,00

45,00

2017 2018 2019 Q2/2020

KIMIA FARMA 5.44 38.05 26.11 3.60

PHARMACY INDUSTRY 3.10 -1.50 6.70 -1.00

25

KAEF KLBF TSPC DVLA MERK SIDO PYFA PEHA INAF

Growth 3,6 3,81 -0,11 1,56 -10,72 3,52 0,17 -17,78 21,28

3,60 3,81

-0,11

1,56

-10,72

3,52 0,17

-17,78

21,28

-20,00

-15,00

-10,00

-5,00

-

5,00

10,00

15,00

20,00

25,00

Peers Growth (2Q/2020)

7.888.135

6.932.831

Q2 2019 Q2 2020

8.909.395

10.581.168

Q2 2019 Q2 2020

16.797.529

17.513.999

Q2 2019 Q2 2020

394.502

496.729

Q2 2019 Q2 2020

296.302

365.034

Q2 2019 Q2 2020

4.524.819

4.687.803

Q2 2019 Q2 2020

REVENUE OPERATING PROFIT

3.60%

23.20%

ASSETS LIABILITIES EQUITY

4.27% 18.76% 12.11%

In IDR billion

EBITDA

25.91%

In IDR billion In IDR billion

In IDR billion In IDR billion In IDR billion

Financial Performance Q2/2020

Note: the decline in equity comes from the implementation of PSAK 71 forcing the company to preserve OCI

26

4,524,819

4,687,803 296,302

365,034

394,502

496,729

16,797,529

17,513,999

8,909,395

10,581,168 7,888,135

6,932,831

EBITDA MARGIN ROI

ROA

Financial Performance Q2/2020

ROE

8,72%

10,60%

Q2 2019 Q2 2020

1,93%

2,14%

Q2 2019 Q2 2020

0,28% 0,28%

Q2 2019 Q2 2020

0,85%

0,68%

Q2 2019 Q2 2020

27

8.72%

10.60%

1.93%

2.14%

0.85%

0.68%

0.28% 0.28%

BUSINESS EXPANSION & INVESTMENT

4

Business Expansion & Investment

4,826 Billion

Banjaran Plant Rapid Test Plant API & HFC Plant

Kimia Farma Dawaa (Saudi Arabia)

Pharmacy, Clinics & Clinical Lab

Health & Beauty Clinic

Acquisition of PT Phapros Tbk

Injection Prod. Facility

Retail Pharmacy Digitalization

SAP, QR Code, Track & Trace, and

Internet of Things (IoT)

Distribution (KFTD) Renovation

In IDR Billion

788

1.352

2.140

546

2017 2018 2019 2020

CAPEX 2017 - 2020

*

*projection 2020

30

1,352

2,140

OUR RETAIL BUSINESS-KIMIA FARMA APOTEK

5

Integrated Healthcare Network

Services Sumatera Jawa Kalimantan Bali ,Nusa Tenggara

Sulawesi, Maluku, Papua

Total

APOTEKS 217 667 130 121 173 1,308

HEALTH CLINICS

65 272 56 24 69 486

BEAUTY CLINICS

3 3

CLINICAL LABORATORIES

11 42 6 3 8 70

OPTICS 2 8 10

Kimia Farma Apotek has a fully integrated, seamless healthcare network covering all 34 provinces in Indonesia – cementing its position as the biggest upstream-downstream pharmacy player in Indonesia

33

Kimia Farma Apotek – Our Retail Side

HISTORY

OUR SERVICES

No. of employees

> 9000

OUR PRODUCTS

70 Outlet di 34 kota besar dan 10- outlet optik

34

• 1.308 Pharmacy • Standard Good Pharmacy Practice (GPP) • More than 38.000 SKU (ethical, OTC,

Medical Device) • Outblets in Airport, Hotel, and Mall

• 468 Klinik Pratama & Utama • Clinic Managed Care • BPJS Network Provider (open

provider) • Vaccination Services with

International Certified • Dental clinic service • Haemodialysis clinic

980.336

807.776

Q2 2019 Q2 2020

2.050.416

2.380.664

Q2 2019 Q2 2020

3.030.752

3.188.440

Q2 2019 Q2 2020

91.405

225.789

Q2 2019 Q2 2020

76.010

105.669

Q2 2019 Q2 2020

2.411.928

2.723.725

Q2 2019 Q2 2020

REVENUE OPERATING PROFIT

12.93% 39.20%

ASSETS LIABILITIES EQUITY

5.20% 16.11% 17.60%

In IDR billion

EBITDA

147.02%

In IDR billion In IDR billion

In IDR billion In IDR billion In IDR billion

Financial Performance Q2/2020

Note: the decline in equity comes from the implementation of PSAK 71 forcing the company to preserve OCI

35

2,411,928

2,723,725

3,030,752

76,010

105,669

2,050,416

2,380,664

91,405

225,789

980,336 3,188,440

807,776

1,27%

1,46%

Q2 2019 Q2 2020

5,02% 5,07%

Q2 2019 Q2 2020

2,54%

3,36%

Q2 2019 Q2 2020

3,79%

8,29%

Q2 2019 Q2 2020

EBITDA MARGIN ROI

ROA

Financial Performance Q2/2020

ROE

36

3.79%

8.29%

2.54%

5.02% 5.07%

1.27%

1.46%

3.36%

Kimia Farma Apotek - Digital Development Roadmap 2020

Digitization to accelerate

and optimize business

Pulverizing

2022

Scaling up business growth through

customer experience approach

Watering 2023

Transform, manage, boost and

enrich KFA business portfolio

Fertilizing 2024

Subsidiarizing and Going Beyond

Harvesting

2021

Explore new business models and

revenue streams enhancement

Seeding

1. Launching - Kimia Farma Mobile: Ethical, OTC, Prescription drugs, vaccine reservation

2. Integrated 7 Solutions platform with all KFA Services: Smartstock, OmniChannel, Customer Loyalty, Big Data Analytics, Clinic Integration, BPJS PRB, Homecare

3. SEO Location: Location tagging optimization for all 1266 outlets in Google My Business (GMB)

1. 7 Solutions Optimization: Clinic Optimization, Strategic partnership for healthcare ecosystem (Insurance, SEO, Hospital, etc), BUMN Connectivity, Customer Loyalty & Membership

2. Telemedicine: comprehensive tech-based long distance service by healthcare professionals (examination, consultation, diagnosis, prescription, references)

3. New Business Model • KF Digital Experience Store • KFPort, Virtual Store in strategic

public space • KFAds: Monetize Display Asset for

both Physical and Digital signage 3rd party advertising

4. SEO Location: Monetizing GMB location to 3rd party principals

5. Integrated Social Media

1. Kimia Farma Mobile as a Healthcare hub: a super app covering all of Indonesia healthcare ecosystem.

2. Big Data Monetizing business insight from the healthcare ecosystem data

1. New Customer Acquisition: 100,000

1. New Customer acquisition: 1 million

2. Physician collaboration: 1,000 affiliated MDs

1. New customer acquisition: 4 million

2. Physician collaboration: 2,000 external MDs, 500 specialists

1. New customer acquisition: 6 million 2. Physician collaboration: 1,500 MDs,

200 specialists 3. Healthcare hub: 2,000 3rd party

pharmacies

1. New customer acquisition: 8 million

2. Revenue: 940 billion

1. 7 Solutions Exploration: business process efficiency, other income optimization, new business model

2. Increasing Omni-Channel scale with Big Data Analysis

3. KF Mobile feature enhancement: • Augmented Reality (AR) Beauty, Optic • AI Machine Learning for prediction

analysis and personalized service • New Features: Mother & Child,

Wellness & Nutrition, Sexual Health 4. Telemedicine optimization 5. KF Mobile service building: new

customer acquisition, specialist doctor collaboration

6. 7Solutions: SAAS (Software As A Service) business model

7. Single-ID Customer Loyalty 8. GMB growth to all new outlets 9. KF Ads and KF Port growth to 2 times

of 2021

1. KFAds Subsidiary 2. KFPort Subsidiary 3. KFMobile Subsidiary

37

On average: 91,000 transactions per day

• Integrated inventory • Forecasting • Integrated master data

Smartstock

• 34 provinces of Indonesia • 1,318 outlets (pharmacies & optics) • 486 clinics (managed by KFD) • 70 laboratories (managed by KFD) • 3 beauty clinics • Online channels: 1,254 pharmacies • Integrated with BPJS-PCare: 9 clinics • Integrated with BPJS-Apotekonline: 5 pharmacies • Homecare dokter: 3 clinics • Home Pharmacy Care: 5 pharmacies

Outlets: • POS for pharmacies • Sistem Klinik • Laboratory Information

System (LIS)

Kimia Farma Online: • e-Commerce • Clinic reservation • Online consultation • PRB Community

• BPJS-Pcare • BPJS-apotekonline

*)

*) *)

*) to-be

• Insurance/TPA

• Cashless payment

• Delivery

Partners:

API

• Potensi lainnya Affiliated physicians

Hospital pharmacy installations e-klinik PCMI

Kimia Farma Apotek Digitalization

Appstore (IoS): 4.9 , 692 reviews, 2,573

downloads

Playstore (Android): 5.0 , 5,174 reviews, 31,600

downloads

38

More than just a health app, Kimia Farma Mobile is our new platform for a healthy lifestyle –

easily, quickly, and above all, digitally.

2,573 download

31,600 downloads

As a Integrated Healthcare SOE, we keep transforming our service quality; in 16 August 2020, we launched Kimia Farma Mobile, our mobile app services – accessible anywhere and anytime

OMNI Channel Connected with our 1254

pharmacies, all across Indonesia

Complete Payment Options CC, Virtual Account, eWallet

Various Shipping Options Gosend, JNE, GrabExpress,

Kimia Farma Delivery

Ease of Access Anytime, Anywhere

Homecare Kimia Farma quality healthcare,

right at your doorstep

Vaccine Reservation Online vaccine services

Diagnostic Services Our integrated clinical laboratory

and healthcare clinic services

Online Consultation With our top pharmacists &

physicians

Kimia Farma Mobile

Top Trending Search for Medical Category App (15-Okt) in Playstore

Top GoogleSearch for “beli obat online” keyword

(15-Okt)

by October 11th, 2020

40

Kimia Farma Drive-Thru

Our new breakthrough – the first EVER drive thru pharmacy in Indonesia

Where? Apotek Kimia Farma 11 Supratman Bandung Jl. Supratman NO. 72, Kota Bandung.

Why? 1. To combat the COVID-19 pandemic by helping people

follow the strict healthcare protocol for physical distancing

2. To give a feeling of safety and comfort for our customers in getting their healthcare needs

3. To create a brand new customer experience

What? Directly buy OTC and prescription drugs, medical devices, food supplements and more from your vehicle without having to get down from your car – teleconsultation with our top qualified pharmacist as you drive by.

41

Kimia Farma and the COVID-19 Pandemic: Mobile Lab PCR

Kimia Farma Diagnostika will expand the reach of our COVID-19 PCR test to even more people and more area in Indonesia, by making it mobile. By the end of 2020, five PCR Mobile Lab Unit will be opened in 5 cities: Surabaya, Denpasar, Banjarmasin, Batam, Jakarta

1. Mobile Unit + Modified Hino Dutro Cabin Long Chasis, Sandwich Panel & Lab Instruments

2. Supporting Instruments 3. Comparative Test 4. Operational

Mobile Lab PCR spec and steps:

42

Kimia Farma for Indonesia

Kimia Farma gained public trust as

the most comprehensive and

largest health service provider in

Indonesia with its business chain

from the upstream to the

downstream of the industry for more

than 49 years.

Non-Stop Dedication

Kimia Farma supports

the availability of drugs and health products

to each and every

region in Indonesia

Equality In Health Distribution

In achieving a Healthy Indonesia, Kimia

Farma conducts research and development, as well

as innovates to produce good quality products, some

of which are the Covid-19 treatment drug

(Chloroquine, Hydroxychloroquine, Azithromycin,

Favipiravir, Covid – 19 Rapid Test, Immunomodulator)

Keep Inovating

Supporting the Government as the

only pharmaceutical industry that

produces HIV Medicines

Real Action For Indonesia

Kimia Farma through its Subsidiary, Kimia Farma

Apotek (KFA) and Kimia Farma Diagnostika (KFD)

reaches all over the country.

Complete and Integrated Health Services

With the facility of Active

Pharmaceutical Ingredients (API)

Kimia Farma encourages the

creation of API in Indonesia in

accordance with the ideals of

Indonesia

National Independence

As a Healthcare Solution,

Kimia Farma always provides comfort

and a different experience. Through

Kimia Farma Mobile Apps and Kimia

Farma Drive Thru, as one of the

solutions for digital customer

experiences

Costumer Focus

44

KANTOR PUSAT

Jl. Veteran No. 9 Jakarta Pusat 10110 Phone: +62 21 3847709 | Fax: +62 21 3814441

Email: corsec@kimiafarma.co.id Website: www.kimiafarma.co.id

Terima Kasih

Semoga Sehat Selalu